Craniopharyngioma clinical trials at UCSF
2 research studies open to eligible people
A craniopharyngioma is a rare brain tumor near the pituitary gland. UCSF is studying an experimental drug for advanced cancers to evaluate safety and effectiveness. UCSF is also testing a medicine that targets RAF proteins as a single treatment in children and young adults with craniopharyngioma.
FOG-001 in Locally Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
San Francisco, California and other locations
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
open to eligible people ages 1-39
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
San Francisco, California and other locations
Our lead scientists for Craniopharyngioma research studies include Sabine Mueller, MD, PhD, MAS.
Last updated: